# Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

> **NCT00616421** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 2907 (actual)

## Conditions studied

- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** Licensed meningococcal ACWY vaccine

## Key facts

- **NCT ID:** NCT00616421
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-04
- **Final completion:** 2009-10
- **Target enrollment:** 2907 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616421, "Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00616421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*